Related Experiment Videos
Pemoline pharmacokinetics and long term therapy in children with attention deficit disorder and hyperactivity
Insights
Pemoline
Area of Science:
- Pharmacology
- Pediatrics
- Neuroscience
Background:
- Attention Deficit Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder in children.
- Pemoline, a central nervous system stimulant, has been used to manage ADHD symptoms.
- Understanding pemoline's pharmacokinetics in children is crucial for effective treatment.
Purpose of the Study:
- To investigate the pharmacokinetic profile of pemoline in children diagnosed with ADHD.
- To compare pemoline's half-life in children to previously reported values in adults.
- To assess the relationship between age, clearance, and half-life in pediatric patients.
Main Methods:
- A pharmacokinetic study was conducted on 28 children aged 5-12 years with ADHD.
- Pemoline serum concentrations were measured over time to determine pharmacokinetic parameters.
- Statistical analysis was used to evaluate the influence of age on half-life and clearance.
Main Results:
- The mean elimination half-life of pemoline in children was approximately 7 hours, shorter than in adults (11-13 hours).
- A statistically significant decrease in total body clearance with increasing age was observed.
- No tolerance to pemoline's beneficial effects was noted over a 6-month treatment period.
- Therapeutic serum concentrations were achieved with daily doses ranging from 37.5 to 131.25 mg.
Conclusions:
- Pemoline's half-life in children with ADHD is shorter than in adults and tends to increase with age due to decreased clearance.
- Individualized dosing is recommended due to wide variations in optimal serum concentrations.
- Routine monitoring of pemoline serum concentrations is not considered useful for optimizing therapy in this population.
Abstract:
The pharmacokinetic behaviour of pemoline was studied in 28 children, aged 5 to 12 years, diagnosed as having the attention deficit disorder with hyperactivity. The mean elimination half-life of pemoline in these children was approximately 7 hours, which is considerably shorter than the half-life of 11 to 13 hours previously reported in adults. The tendency of the half-life to increase with age may be explained by the statistically significant decrease in total body clearance with age. The increasing half-life of pemoline with age should be considered during long term drug therapy. In this study no tolerance to the beneficial effects of pemoline was observed over 6 months. The apparent therapeutic serum concentration range for these children was attained after doses of 37.5 to 131.25 mg pemoline daily. Since the optimum serum concentration shows wide variation, the dosing regimen must be determined individually. Routine monitoring of the pemoline serum concentrations is not useful because of this apparent variation in optimum serum concentration and because of the linear relationship between dose and concentration.